Peptic ulcer disease

  title={Peptic ulcer disease},
  author={{\'A}ngel Lanas and Francis K L Chan},
  journal={The Lancet},

Figures and Tables from this paper

Helicobacter pylori and nonmalignant upper gastrointestinal diseases
There is no evidence indicating that H. pylori eradication could worsen the symptoms or the course of GERD, and intriguing findings support the involvement of the gastric microbiota in the causation of chronic functional dyspepsia.
Evaluation of Peptic Ulcer Disease
Evaluation of peptic ulcer disease now largely rests on the diagnosis of these two predisposing factors of H. pylori infection and impaired mucosal healing from NSAID use.
Who Needs Gastroprotection in 2020?
H. pylori test and treat should be offered to older patients starting NSAIDS, while PPIs should be prescribed to patients that are at high risk of developing PUD and at risk of dying from PUD complications.
Pharmacological Management of Peptic Ulcer: A Century of Expert Opinions in Cecil Textbook of Medicine
The pharmacological management of peptic ulcer has remained archaic well into the 20th century and was due to paradigm shifts from acid neutralization to acid suppression and later the recognition of the role of H. pylori infection.
The Role of Host Genetic Polymorphisms in Helicobacter pylori Mediated Disease Outcome.
This chapter is a review of current evidence that host genetic polymorphisms play a role in mediating persistent H. pylori infection and the consequences of the subsequent inflammatory response.
A case of a 70 year old man, who presented with recurrent episodes of duodenal perforation in an interval of 2 years is discussed, which is a surgeon's dilemma and has to be managed to each presentation.


Pathogenesis and therapy of gastric and duodenal ulcer disease.
TNF and LTA gene polymorphisms reveal different risk in gastric and duodenal ulcer patients
It is suggested that TNF and LTA gene polymorphisms are related to the development of gastric and duodenal ulcer and may determine disease outcome in H. pylori infection.
Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users
There were differences in the interaction effect between low-dose ASA (no interaction) or NSAID (addition) use and H. pylori infection, which may have implications for clinical practice in prevention strategies.
Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users.
The long-term incidence of recurrent ulcer bleeding with ASA use is low after H pylori infection is eradicated, and tests for H plyori infection can be used to assign high-risk ASA users to groups that require different gastroprotective strategies.
High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers.
Patients with history of H pylori-negative idiopathic bleeding ulcers have a high risk of recurrent ulcer bleeding and mortality and are followed for 7 years without gastroprotective therapy.
Gastroprotective therapy does not improve outcomes of patients with Helicobacter pylori-negative idiopathic bleeding ulcers.
  • G. Wong, K. Au, F. Chan
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2012
Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection
It was recommended that H. pylori infection should be tested for and eradicated prior to long‐term aspirin or non‐steroidal anti‐inflammatory drug therapy in patients at high risk for ulcers and ulcer‐related complications and in communities with high incidence of gastric cancer prevention.